Caring for patients with geographic atrophy (GA)?
Talk to your patients about SIENNA
With limited treatment options and no cure for geographic atrophy (GA), the SIENNA clinical study is currently underway to investigate potential treatments. As the principal investigator, I would like to invite you to consider the SIENNA study as an opportunity for your patients with GA to access emerging treatments.
The SIENNA study is a phase 3 clinical research study for adults with GA. This study is evaluating how safe and effective the study drugs alone or in combination are in slowing the progression of GA.
The SIENNA study will last up to 154 weeks (just under 3 years)* with 32 study visits. Over the course of the study, the study treatments or placebo will be administered as a subcutaneous injection. Participants may receive a combination of the two investigational study drugs, the second investigational drug alone plus a placebo, or two placebo doses.
* Note: At the end of the study, participants who have completed the week 104 visit and who have not discontinued treatment will have the option to enter the extension period where active treatment (without placebo) will be received for up to 3 years before proceeding to the post-treatment period. After treatment ends, participants will be followed for about 36 weeks. If they choose this option, total participation could last up to about 6 years.
Qualified participants may be reimbursed for travel to and from study visits, and medical care related to their participation, including the study treatment, may be provided at no cost.
How can you help?
The SIENNA study is first enrolling a smaller group of 225 participants, then moving to the main group of about 750 participants – approximately 975 people with geographic atrophy (GA) in 11 countries. The success of the SIENNA study depends on physicians referring potential study participants. Your patients may be eligible if they are:
- Age 50 to 85 years at screening
- Confirmed diagnosis of GA of the macula secondary to AMD
- BCVA of 55 letters or better using ETDRS charts (20/80 Snellen equivalent) in the study eye at screening and randomization
- Total GA area in the study eye measuring between ≥2.5 mm2 and ≤17.5 mm2
- Willing and able to attend study visits, complete study procedures, and receive the required vaccinations before starting, including meningococcal (ACWY and at least 2 doses of MenB) and a pneumococcal vaccine.
Please note: Other protocol-defined inclusion/exclusion criteria apply.
The study team will check your patient’s full medical history to see if they meet all inclusion criteria and none of the exclusion criteria. Diversity in clinical studies is critical to developing better treatments – help ensure that your patients are represented.
If you have potentially eligible and interested patients, empower them with options and discuss the SIENNA study. You may also contact the nearest study site to refer them.
Please note that this clinical trial will use investigational drug products, the safety and efficacy of which has not been fully evaluated by Regulatory Authorities. One of the investigational drug products has been approved for certain uses in some countries. Please consult with the study physician for more information.
Find a study site near you!
Your patient’s health and safety are our top priorities. We hope you value the impact of this research and will consider referring potential candidates. With your support, we hope to help patients with GA.
English